Syndesi Therapeutics

Syndesi Therapeutics

Foundation date

19/12/2017

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Small molecules

Therapeutic areas

• #Diseases of the nervous system

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.